HomeCompareBSX vs KLAC

BSX vs KLAC: Dividend Comparison 2026

BSX yields 3.18% · KLAC yields 0.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KLAC wins by $775.0K in total portfolio value· pulled ahead in Year 2
10 years
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →
KLAC
KLAC
● Live price
0.55%
Share price
$1,382.58
Annual div
$7.60
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$795.3K
Annual income
$589,306.66
Full KLAC calculator →

Portfolio growth — BSX vs KLAC

📍 KLAC pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSXKLAC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSX + KLAC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSX pays
KLAC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
KLAC
Annual income on $10K today (after 15% tax)
$46.72/yr
After 10yr DRIP, annual income (after tax)
$500,910.66/yr
At 15% tax rate, KLAC beats the other by $500,910.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSX + KLAC for your $10,000?

BSX: 50%KLAC: 50%
100% KLAC50/50100% BSX
Portfolio after 10yr
$407.7K
Annual income
$294,653.49/yr
Blended yield
72.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
KLAC
Analyst Ratings
27
Buy
14
Hold
2
Sell
Consensus: Buy
Price Target
$1,696.31
+22.7% upside vs current
Range: $1,400.00 — $1,900.00
Altman Z
12.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSX buys
0
KLAC buys
0
No recent congressional trades found for BSX or KLAC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSXKLAC
Forward yield3.18%0.55%
Annual dividend / share$2.00$7.60
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%100%
Portfolio after 10y$20.2K$795.3K
Annual income after 10y$0.32$589,306.66
Total dividends collected$321.00$757.1K
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusBuyBuy
Analyst price target$108.35$1,696.31

Year-by-year: BSX vs KLAC ($10,000, DRIP)

YearBSX PortfolioBSX Income/yrKLAC PortfolioKLAC Income/yrGap
1$10,859$158.91$10,810$109.94+$49.00BSX
2← crossover$11,700$80.63$11,789$222.14$89.00KLAC
3$12,559$40.60$13,067$452.81$508.00KLAC
4$13,459$20.36$14,920$938.13$1.5KKLAC
5$14,411$10.20$17,966$2,002.14$3.6KKLAC
6$15,425$5.10$23,730$4,506.49$8.3KKLAC
7$16,507$2.55$36,517$11,125.83$20.0KKLAC
8$17,664$1.28$71,075$32,001.78$53.4KKLAC
9$18,901$0.64$192,474$116,423.57$173.6KKLAC
10$20,225$0.32$795,254$589,306.66$775.0KKLAC

BSX vs KLAC: Complete Analysis 2026

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →

KLACTechnology

KLA Corporation designs, manufactures, and markets process control, process-enabling, and yield management solutions for the semiconductor and related electronics industries worldwide. It operates through four segments: Semiconductor Process Control; Specialty Semiconductor Process; PCB, Display and Component Inspection; and Other. The company offers integrated circuit (IC) manufacturing products that comprises wafer inspection and review, and metrology; wafer and substrate defect inspection and metrology; reticle defect inspection and metrology; chemical/materials quality analysis; in situ process management and wafer handling diagnostics for IC and original equipment manufacturer (OEM) manufacturing; software products to provide run-time process control, defect excursion identification, process corrections, and defect classification; and refurbished and remanufactured products. It also provides specialty semiconductor manufacturing, benchtop metrology, surface characterization, and electrical property measurement services for general purpose/ lab applications; etch, plasma dicing, deposition, and other wafer processing technologies and solutions for the semiconductor and microelectronics industry. In addition, the company offers direct imaging, inspection, optical shaping, additive printing, and computer-aided manufacturing and engineering solutions for the PCB market; inspection and electrical testing systems to identify and classify defects, as well as systems to repair defects for the display market; and inspection and metrology systems for quality control and yield improvement in advanced and traditional semiconductor packaging markets. The company was formerly known as KLA-Tencor Corporation and changed its name to KLA Corporation in July 2019. KLA Corporation was incorporated in 1975 and is headquartered in Milpitas, California.

Full KLAC Calculator →
📬

Get this BSX vs KLAC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSX vs SCHDBSX vs JEPIBSX vs OBSX vs KOBSX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.